Bupropion SR as an Anti-Craving Anti-Obesity Agent

安非他酮 SR 作为抗渴抗肥胖剂

• 批准号: 7392309
• 负责人: KRISTINE Jayne STEFFEN
• 金额: $ 5.59万
• 依托单位: SANFORD RESEARCH NORTH
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7392309
• 关键词: Address; Adult; Adverse effects; Algorithms; Anti-Obesity Agents; Antidepressive Agents; Attenuated; Behavioral Mechanisms; Binge eating disorder; Body Weight decreased; Body mass index; Bupropion; Cessation of life; Clinical Research; Condition; Consumption; Coupled; Cues; Daily; Dopamine; Double-Blind Method; Eating; Eating Behavior; Equipment and supply inventories; Exhibits; Fellowship; Food; High Prevalence; Hour; Hunger; Incidence; Individual; Investigation; Laboratories; Measurement; Measures; Modality; Modification; Molecular; Names; Obesity; Outcome; Overweight; Pharmaceutical Preparations; Pharmacotherapy; Placebo Control; Placebos; Prevalence; Questionnaires; Rate; Reporting; Rewards; Risk; Role; Satiation; Slide; Stimulus; Testing; Therapeutic Intervention; Thinking; United States; United States National Institutes of Health; Week; Weight; clinical efficacy; craving; experience; feeding; food craving; hedonic; human subject; improved; insight; mortality; noradrenergic; obesity treatment; smoking cessation

DESCRIPTION (provided by applicant): As the prevalence of obesity increases and available pharmacotherapies remain of modest benefit, investigating the pharmacological modification of mechanisms that control food intake is imperative. Bupropion, an antidepressant and anti-craving agent for smoking cessation, has been observed to produce weight loss through an uncharacterized mechanism. The clinical efficacy of this compound is thought to result from noradrenergic and dopaminergic activity. Dopamine has an established role in modulating food reward. The objective of the proposed study is to test the primary hypothesis that bupropion will reduce food reward and craving in overweight and obese human subjects. To examine this postulate, a feeding laboratory paradigm, 72 hour dietary recall, and validated craving questionnaires will be used. Implications for the results of this study include providing insight into a potentially unique behavioral mechanism of action of the existing anorexigenic compound bupropion. Longer term implications for the results of this study include the potential investigation of this agent as a therapeutic intervention for conditions such as obesity and binge eating disorder.

描述（由申请人提供）：随着肥胖症患病率的增加，并且现有的药物疗法仍然没有多大益处，因此研究控制食物摄入机制的药理学修改势在必行。安非他酮是一种用于戒烟的抗抑郁药和抗烟瘾药，已被观察到通过一种未知的机制产生体重减轻。该化合物的临床功效被认为是由于去甲肾上腺素能和多巴胺能活性。多巴胺在调节食物奖励方面具有明确的作用。拟议研究的目的是检验安非他酮会降低超重和肥胖人类受试者的食物奖励和渴望的主要假设。为了检验这一假设，将使用喂养实验室范例、72 小时饮食回忆和经过验证的渴望问卷。这项研究结果的意义包括深入了解现有的抑制食欲化合物安非他酮的潜在独特的行为机制。这项研究结果的长期影响包括对该药物作为肥胖和暴食症等疾病的治疗干预的潜在研究。